Search Results

You are looking at 61 - 70 of 489 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Oncology Research Program

scientific peer-review process and are overseen by the ORP. Several NCCN-sponsored studies funded through the grant mechanism are highlighted below. Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) Plus Weekly Cetuximab Plus Radiation Therapy

Full access

New Issues in Systemic Therapy for Ovarian Cancer

Deborah K. Armstrong

Most patients with ovarian cancer are diagnosed with advanced-stage cancer. Debulking surgery followed by chemotherapy is recommended. The standard front-line regimen is 6 cycles of paclitaxel plus carboplatin, with docetaxel a reasonable

Full access

Point: Combination Versus Single-Agent Chemotherapy: The Argument for Sequential Single Agents

Alison K. Conlin and Andrew D. Seidman

anthracycline-containing chemotherapy. 304 Study Group . J Clin Oncol 1999 ; 17 : 1413 – 1424 . 6. Bishop JF Dewar J Toner GC . Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated

Full access

CLO21-024: Serial Circulating Tumor DNA Analysis for Treatment Monitoring in an Inflammatory Triple-Negative Breast Cancer Patient

Urmeel Patel, Nicole Hook, Meenakshi Malhotra, Perry Olshan, Paul R. Billings, Alexey Aleshin, and Angel Rodriguez

patient underwent neoadjuvant chemotherapy with dose dense AC (ddAC) followed by paclitaxel. Following one month, the patient underwent radical mastectomy, followed by adjuvant treatment and periodic radiological imaging, along with circulating tumor DNA

Full access

Oncology Research Program

, Vanderbilt-Ingram Cancer Center • 800-811-8480 ClinicalTrials.gov Identifier: NCT00983268 A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer Principal Investigator

Full access

Oncology Research Program

-639-5449 ClinicalTrials.gov Identifier: NCT01111825 Phase I Trial of Intraperitoneal Nab-Paclitaxel (Abraxane) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity Principal Investigator: Mihaela Cristea, MD Condition

Full access

Oncology Research Program

-agent tivozanib in patients with platinum-resistant ovarian cancer Contact: Nikki Neubauer, MD • 312-472-4684 Rachel Bers, BS • 312-472-5726 • r-bers@northwestern.edu ClinicalTrials.gov Identifier: NCT01853644 Phase I Trial of Intraperitoneal Nab-Paclitaxel

Full access

Therapy of Adenocarcinoma of Unknown Primary: Are We Making Progress?

F. Anthony Greco

Med 2004 ; 350 : 2335 – 2342 . 4. Sandler AB Gray R Perry MC . Paclitaxel-carboplatin alone or with bevacizumab for non-small lung cancer . N Engl J Med 2006 ; 355 : 2542 – 2550 . 5. Moore MJ Goldstein D Hamm J . Erlotinib

Full access

Management of Recurrent or Metastatic Cervical Cancer

Presented by: Nadeem R. Abu-Rustum

with external-beam RT, as well as interstitial brachytherapy, which is a sophisticated technology for the treatment of central pelvic recurrences. Use of modern chemotherapy regimens containing a combination of platinum and paclitaxel with drugs such

Full access

Advances in the Treatment of Non-Small Cell Lung Cancer

Leora Horn

in Oncology (NCCN Guidelines) for NSCLC, many chemotherapy drugs are useful for treating patients with advanced-stage NSCLC. Among them are platinum agents (eg, cisplatin, carboplatin), taxanes (eg, paclitaxel, albumin-bound paclitaxel, docetaxel